75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation observed in all patients with 81% of EVX-01’s vaccine targets triggering a specific...Read more
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the Phase 3 monarchE trial also show Verzenio plus endocrine therapy demonstrated...Read more
More than two thirds of patients treated with IMFINZI-based perioperative regimen were alive at three years First and only perioperative immunotherapy approach to show survival benefit in this setting WILMINGTON, Del. / Oct 17, 2025 / Business Wire / Positive results from the...Read more
Final FDA Type C Meeting December 11, 2025 - biomarker data to be available October 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine osteosarcoma data New York, New York--(Newsfile Corp. - October 17, 2025) - OS...Read more
BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed In parallel, new written FDA feedback...Read more
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Praxis Precision Medicines | 23.05 14.17 | $185.76 |
| Disc Medicine | 15.95 21.45 | $90.31 |
| McKesson | 11.72 1.51 | $787.16 |
| Intuitive | 9.50 2.19 | $444.12 |
| Cigna | 8.00 2.75 | $299.07 |
| Humana | 7.84 2.93 | $275.12 |
| Regeneron Pharmaceuticals | 6.93 1.22 | $576.10 |
| Vertex Pharmaceuticals | 6.14 1.50 | $414.75 |
| Bolt Biotherapeutics | 5.27 941.07 | $5.83 |
| Chemed | 5.06 1.17 | $435.98 |
| HCA Healthcare | 4.55 1.08 | $424.15 |
| Revolution Medicines | 4.27 8.60 | $53.95 |
| Movano Health | 4.19 134.73 | $7.30 |
| Gilead Sciences | 4.08 3.46 | $121.93 |
| Apollomics | 3.69 11.54 | $35.67 |
| Alnylam Pharmaceuticals | 3.43 0.71 | $484.50 |
| AbbVie | 3.28 1.45 | $230.15 |
| Stryker | 3.24 0.88 | $372.49 |
| Company | Volume | Last Trade |
|---|---|---|
| Rani Therapeutics | 299,446,641 | $2.14 |
| XORTX Therapeutics | 82,013,077 | $1.19 |
| Artiva Biotherapeutics | 60,158,541 | $5.60 |
| Genprex | 43,263,677 | $0.36 |
| Recursion | 40,215,536 | $5.90 |
| Femasys | 21,455,325 | $0.68 |
| Adaptimmune Therapeutics | 20,946,465 | $0.18 |
| WORK Medical Technology | 17,825,529 | $0.04 |
| Pfizer | 16,802,096 | $24.40 |
| Quantum-Si | 14,477,745 | $2.28 |
| atai Life Sciences | 13,036,585 | $5.79 |
| Achieve Life Sciences | 12,438,548 | $4.14 |
| Incannex Healthcare | 10,308,797 | $0.35 |
| Oscar Health | 9,134,803 | $19.14 |
| Novo Nordisk | 9,094,850 | $54.02 |
| Bristol-Myers Squibb | 5,103,974 | $43.43 |
| MIRA Pharmaceuticals | 4,509,338 | $1.56 |
| Kezar Life Sciences | 4,287,000 | $6.04 |
| Iovance Biotherapeutics | 4,248,731 | $2.15 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
